Bajaj Healthcare Ltd. is in the business of manufacturing pharmaceutical products and bulk drugs. It is valued at Rs. 917 crore on the stock exchange. The company was incorporated in 1993. The key figures in the company’s management are Mr Pakshal A Jain, Mr Rupesh H Nikam, and Mr Sajan Kumar R Bajaj. Bajaj Healthcare’s net profit was Rs. 17.45 crore in the third quarter of FY 2021-22. The share price of Bajaj Healthcare is traded under the script name of BAJAJHCARE on both the stock exchanges (NSE & BSE).
Bajaj Healthcare’s product segment comprises formulations and bulk drugs. Its therapeutic API portfolio includes anticonvulsants, vitamins, bactericidal, bronchodilators, and so on. It offers anti-Platelets, anti-arrhythmia, anti-hypertensive, and a few more in the FDF segment.
Bajaj Healthcare Ltd.’s price-to-earnings (PE) ratio and price-to-book (PB) ratio are better than its industry average. The PE ratio is 10.89, and the PB ratio is 3.52. For the past five years, the company’s average annual revenue and profit growth rates were 24.36% and 58.88%, respectively. Bajaj Healthcare reported a net income of Rs. 7.80 crore, Rs. 15.20 crore, Rs. 16.30 crore, Rs. 25.25 crore, and Rs. 83.11 crore in the past five financial years. The company declared a dividend of Rs. 1.38 and an EPS of Rs. 30.11. The company’s overall assets have increased significantly over the past two years. However, total liabilities have also increased during the same period. During the past five years, the company’s average debt-to-income ratio and current ratio have been 67.1% and 117.13%, respectively. For the financial year 2021, the company’s financials showed a negative free cash flow.
On April 6, 2022, Bajaj Healthcare’s share price on BSE closed at Rs. 373.75. Bajaj Healthcare’s share price performance on the price chart was quite satisfying, as it reported an annual return of 64.39% in the past 12 months. The 52-week low of Bajaj Healthcare’s share price was Rs. 213.45. The high for the same period was recorded at Rs. 511.90. Investing in Bajaj Healthcare is extremely risky due to its high volatility of 3.43x the NIFTY. Some of the industries’ key competitors of Bajaj Healthcare on the stock exchange are Cipla Ltd., Gland Pharma Ltd., Sun Pharmaceuticals Industries Ltd., Dr Reddy’s Laboratories Ltd., and Torrent Pharmaceuticals Ltd.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: email@example.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.